Adverts

Open Access Articles- Top Results for Molindone

Molindone

</th></tr></th></tr>
Molindone
File:Molindone.svg
Systematic (IUPAC) name
3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-
1,5,6,7-tetrahydro-4H-indol-4-one
Clinical data
Trade names Moban
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a682238
  • C
  • (Prescription only)
Oral
Pharmacokinetic data
Metabolism Hepatic
Half-life 1.5 hours
Excretion Minor, renal and fecal
Identifiers
7416-34-4 7pxY
N05AE02
PubChem CID 23897
IUPHAR ligand 207
DrugBank DB01618 7pxN
ChemSpider 22342 7pxY
UNII RT3Y3QMF8N 7pxY
KEGG D08226 7pxY
ChEMBL CHEMBL460 7pxY
Chemical data
Formula C16H24N2O2
276.374 g/mol
 14pxN (what is this?)  (verify)

Molindone (Moban) is a therapeutic antipsychotic, used in the treatment of schizophrenia.[1] It works by blocking the effects of dopamine in the brain, leading to diminished psychoses. It is rapidly absorbed when taken orally.

It is sometimes described as a typical antipsychotic,[2] and sometimes described as an atypical antipsychotic.[3]

Molindone was discontinued by its sole supplier, Endo Pharmaceuticals, on January 13, 2010. [4]

Adverse effects

Main article: Typical antipsychotic

The side effect profile of molindone is similar to that of other typical antipsychotics. Unlike most antipsychotics, however, molindone use is associated with weight loss.[3][5]

See also

References

  1. ^ "molindone". F.A. Davis Company. 
  2. ^ Aparasu RR, Jano E, Johnson ML, Chen H (October 2008). "Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients". Am J Geriatr Pharmacother 6 (4): 198–204. PMID 19028375. doi:10.1016/j.amjopharm.2008.10.003. 
  3. ^ a b Bagnall A, Fenton M, Kleijnen J, Lewis R (2007). Bagnall, Anne-Marie, ed. "Molindone for schizophrenia and severe mental illness". Cochrane Database Syst Rev (1): CD002083. PMID 17253473. doi:10.1002/14651858.CD002083.pub2. 
  4. ^ http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050794.htm
  5. ^ Allison DB; Mentore JL; Heo M et al. (1999). "Antipsychotic-induced weight gain: a comprehensive research synthesis". Am J Psychiatry 156 (11): 1686–96. PMID 10553730.  Free full text